Mesenchymal Tumors

Slide 1 · Mesenchymal Tumors

of the Urinary Bladder

Benign smooth-muscle tumors · true sarcomas · diagnostic mimics

A morphology-centered pathology lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish benign bladder mesenchymal tumors from true sarcomas and spindle-cell mimics.

Recognize the gross and microscopic features of leiomyoma, leiomyosarcoma, and embryonal rhabdomyosarcoma.

Use architecture, cytology, lineage markers, and sampling context together.

Explain why sarcomatoid carcinoma and inflammatory myofibroblastic tumor enter the differential.

Slide 3 · A practical map of bladder mesenchymal lesions

Benign tumors

Leiomyoma predominates among uncommon benign mesenchymal bladder tumors.

True sarcomas

Embryonal rhabdomyosarcoma in children; Leiomyosarcoma in adults.

Diagnostic mimics

Sarcomatoid carcinoma and inflammatory myofibroblastic tumor may resemble sarcoma.

Slide 4 · Where a mesenchymal tumor arises

Lumen

Urothelium

Lamina propria

Muscularis propria (detrusor)

Perivesical tissue

The principal lineages:

Surface epithelium → epithelial lesions

Subepithelial & muscle compartments → mesenchymal lesions

Layer relationships are simplified; Not drawn to scale.

Slide 5 · “Mesenchymal” is a lineage concept

A mesenchymal tumor shows differentiation toward connective tissue, smooth muscle, or skeletal muscle.

Gross configuration alone cannot prove the lineage of a bladder mass.

Spindle-cell morphology is shared by neoplastic and non-neoplastic processes.

Tissue architecture and differentiation are assessed together.

Slide 6 · How common are these bladder tumors?

These comparisons are qualitative: Robbins gives no exact proportions here.

Benign mesenchymal

Uncommon even when all benign types are considered together.

True sarcoma

Distinctly uncommon within primary bladder neoplasia.

Other spindle-cell lesions

Inflammatory myofibroblastic tumors and sarcomatoid carcinomas exceed true sarcomas.

Slide 7 · First diagnostic distinction

Category

What is established

Central question

Leiomyoma

Benign smooth muscle

Is the mass bland and circumscribed?

Leiomyosarcoma

Malignant smooth muscle

Are atypia, mitoses, necrosis and infiltration present?

Embryonal RMS

Malignant skeletal-muscle differentiation

Is primitive myogenic differentiation demonstrated?

IMT / sarcomatoid carcinoma

Potential sarcoma mimics

What is the true lineage?

Slide 8 · Intramural (submucosal) location matters

Lumen

Urothelium

Lamina propria

Muscularis propria (detrusor)

Perivesical tissue

Discrete

Intramural mass

Leiomyoma:

Usually intramural/submucosal

Circumscribed and encapsulated grossly

Layer relationships are simplified; Not drawn to scale.

Slide 9 · Why a bladder wall lesion may protrude

Topographic interpretation of the gross description; Not a measured growth trajectory.

Wall-based growth

The neoplasm begins within the bladder wall.

Mass expansion

A discrete lesion enlarges in its tissue plane.

Surface deformation

The overlying lumen can become displaced.

Slide 10 · Two gross patterns: Benign versus malignant

Feature

Leiomyoma

True sarcoma

Typical boundary

Encapsulated / discrete

May form a bulky mass

Shape

Oval to spherical

Large protruding lesion

Texture

Smooth-muscle mass

Soft, fleshy, gray-white

Diagnostic value

Raises suspicion for benignity

Raises suspicion for malignancy

Slide 11 · Benign mesenchymal tumors: The core statement

Many benign mesenchymal tumor types can occur in the bladder.

Their microscopic appearances resemble the same tumor types elsewhere.

Collectively these benign bladder tumors are rare.

Leiomyoma is the most common benign mesenchymal tumor of the bladder.

Slide 12 · Leiomyoma: Concise diagnostic profile

Lineage

Benign neoplasm showing smooth-muscle differentiation.

Gross pattern

Typically solitary, intramural, encapsulated and rounded.

Microscopy

Bland intersecting smooth-muscle fascicles with low mitotic activity.

Slide 13 · Leiomyoma: Growth within the bladder wall

Lumen

Urothelium

Lamina propria

Muscularis propria (detrusor)

Perivesical tissue

Discrete

Intramural mass

Leiomyoma:

Usually intramural/submucosal

Circumscribed and encapsulated grossly

Layer relationships are simplified; Not drawn to scale.

Slide 14 · Leiomyoma: Gross characterization

Bladder examples often appear as isolated masses.

They occupy an intramural or submucosal position.

Their contour is oval to spherical, with a distinct capsule.

The size may reach several centimeters.

Slide 15 · Leiomyoma: Intersecting fascicles

Schematic: Bland intersecting fascicles

Fascicles

Intersecting bundles of smooth muscle cells

Nuclei

Elongated, blunt-ended, relatively uniform

Cell behavior

Minimal atypia; Few mitoses

Slide 16 · Leiomyoma: Microscopic cytology

Cells have densely eosinophilic spindle-shaped cytoplasm.

Nuclei are elongated and blunt-ended, with minimal atypia.

Intersecting bundles create a smooth-muscle architectural pattern.

Mitoses are few in the general soft-tissue leiomyoma description.

Slide 17 · Leiomyoma: A three-part evidence pattern

A synthesis of morphology, not a validated numerical scoring system.

Architecture

Intersecting bundles of smooth-muscle cells.

Cytology

Relatively uniform elongated nuclei.

Proliferation

Few mitoses; No strong malignant morphologic pattern.

Slide 18 · Tumor versus background detrusor

Observation

Why it matters

Mass-forming architecture

A neoplasm must be distinguished from native bladder smooth muscle.

Circumscribed border

Supports recognition of a discrete tumor.

Tumor cells resemble smooth muscle

Phenotypic resemblance does not alone establish benign behavior.

Adequate sampling

Required to assess the entire lesion for adverse features.

Slide 19 · Leiomyoma: Immunophenotype is supportive

The markers are described for smooth-muscle tumors in Ch26; The interpretive limitations are an educational inference.

Smooth-muscle markers document differentiation, not inherently benign behavior.

Smooth muscle actin, desmin, and caldesmon are useful markers in smooth-muscle tumor evaluation.

A positive smooth-muscle stain must be integrated with morphology.

No single immunostain substitutes for assessing mitotic activity and atypia.

Slide 20 · Leiomyoma: Diagnostic reasoning

Gross pattern

Discrete intramural mass

Microscopic pattern

Bland fascicular smooth muscle

Ancillary support

Smooth-muscle phenotype, if needed

Synthesis

Benign smooth-muscle neoplasm

Slide 21 · Case A — an intramural bladder mass

An adult has a well-circumscribed intramural bladder mass. Resection shows interlacing fascicles of bland spindle cells, elongated blunt-ended nuclei, and few mitoses.

Interpretation questions

What lineage do the microscopic findings support?

Which features favor leiomyoma over leiomyosarcoma?

What limitation would a small superficial biopsy create?

Slide 22 · Case A — morphology-based interpretation

Smooth-muscle differentiation is suggested by eosinophilic fascicular spindle cells.

Circumscription, nuclear blandness, and low mitotic activity support leiomyoma.

A limited biopsy can underrepresent heterogeneity or the lesion boundary.

A final diagnosis depends on the full observed specimen, not the vignette alone.

Slide 23 · Sarcomas: A rare but important category

True primary sarcomas are distinctly uncommon in the bladder.

A sarcoma is a malignant mesenchymal neoplasm, not simply a spindle-cell mass.

Sarcomatoid carcinoma and inflammatory myofibroblastic tumor are more frequent imitators.

Correct lineage assignment precedes tumor-specific interpretation.

Slide 24 · Rarity does not imply a single morphology

Smooth-muscle malignancy

Leiomyosarcoma is the most common bladder sarcoma in adults.

Skeletal-muscle malignancy

Embryonal rhabdomyosarcoma is the most common in infancy and childhood.

Mimics

Sarcomatoid epithelium and myofibroblastic proliferations demand distinction.

Slide 25 · Bladder sarcomas: Gross morphology

They often present as large masses protruding into the vesical lumen.

Examples as large as 15 cm.

Soft, fleshy, gray-white tissue suggests a mesenchymal tumor.

Gross appearance cannot resolve sarcoma subtype or exclude carcinoma.

Slide 26 · A bulky sarcoma may project into the lumen

Lumen

Urothelium

Lamina propria

Muscularis propria (detrusor)

Perivesical tissue

Bulky protruding

Mass: Schematic

Sarcomas may project into the bladder lumen as large bulky masses.

Exact site/depth needs tissue assessment.

Layer relationships are simplified; Not drawn to scale.

Slide 27 · What the cut surface can tell us

Finding

Interpretation / limitation

Large, soft, fleshy mass

Consistent with a sarcomatous gross phenotype.

Gray-white color

A nonspecific tissue appearance, not a lineage marker.

Luminal projection

Describes the growth configuration rather than histogenesis.

Heterogeneity on sectioning

Calls for representative sampling; it is not itself a subtype diagnosis.

Slide 28 · Adult bladder sarcoma: Leiomyosarcoma

Leiomyosarcoma is a malignant smooth-muscle tumor.

It is the most common bladder sarcoma in adults.

The soft-tissue counterpart usually shows interweaving fascicles of malignant spindle cells.

Definitive diagnosis integrates malignant morphology and myogenic differentiation.

Slide 29 · Leiomyosarcoma: Malignant spindle-cell pattern

Schematic: Atypia and architectural disorder

Pleomorphism

Variation in nuclear size and shape

Mitotic activity

Brisk proliferation may be evident

Necrosis

Supports malignant behavior in context

Slide 30 · Leiomyosarcoma: Cellular features

Eosinophilic spindle cells form interweaving bundles.

Nuclei tend to be blunt-ended but are hyperchromatic.

Cytologic atypia distinguishes malignant cells from bland leiomyoma.

Brisk mitotic activity and necrosis are common in deep soft-tissue examples.

Slide 31 · Leiomyosarcoma: An integrated pattern

Cell identity

Interweaving, eosinophilic smooth-muscle spindle cells.

Malignant cytology

Nuclear atypia and hyperchromasia.

Aggressive behavior

Brisk mitotic activity or necrosis strengthens concern.

Slide 32 · Leiomyosarcoma: Ancillary stains

Smooth muscle actin supports smooth-muscle differentiation.

Desmin may support a myogenic tumor phenotype.

Caldesmon can further support mature smooth-muscle differentiation.

These markers do not independently establish malignant grade or exclude all mimics.

Slide 33 · Why complex genomics does not define every sarcoma

Common pattern

Many adult sarcomas have complex karyotypes.

Example

Leiomyosarcoma frequently shows genomic instability.

Contrast

Some other sarcomas carry specific recurrent fusions.

Slide 34 · Leiomyoma versus leiomyosarcoma

Feature

Leiomyoma

Leiomyosarcoma

Cellular organization

Bland intersecting fascicles

Interweaving malignant spindle cells

Nuclei

Blunt-ended, minimal atypia

Hyperchromatic; atypia may be conspicuous

Mitoses

Few

Often brisk

Necrosis

Not a typical benign feature

Common in deep soft-tissue cases

Stains

Smooth-muscle lineage

Smooth-muscle lineage

Slide 35 · Do not use one finding as a shortcut

An IHC marker establishes lineage more readily than biological behavior.

Gross circumscription is reassuring but not alone sufficient.

High-grade nuclear features may be heterogeneous within a mass.

Sampling, architecture, mitotic activity, and necrosis must be reviewed together.

Slide 36 · Pediatric bladder sarcoma: The key entity

In infancy and childhood, embryonal rhabdomyosarcoma is the leading bladder sarcoma.

This malignancy demonstrates skeletal-muscle differentiation.

It may present in a botryoid configuration.

Anatomic site and age markedly alter the pretest diagnostic possibilities.

Slide 37 · Rhabdomyosarcoma and the urinary bladder

Cellular lineage

Skeletal-muscle differentiation even at sites with little normal skeletal muscle.

Relevant subtype

Embryonal rhabdomyosarcoma is important in the pediatric genitourinary tract.

Special pattern

The botryoid pattern is associated with a polypoid mass in a hollow viscus.

Slide 38 · Sarcoma botryoides: The gross configuration

A conceptual sequence explaining topology; Not a claim of a fixed time course.

Subepithelial site

Develops along the wall of a hollow organ.

Polypoid growth

Rounded projections expand into the lumen.

Grape-like mass

Multiple nodules create a botryoid appearance.

Slide 39 · Sarcoma botryoides: Spatial anatomy

Epithelial surface

Polypoid, grape-like projections

Schematic of the “botryoid” gross pattern; Not a patient specimen.

Slide 40 · Botryoid does not specify every tumor detail

“Botryoid” denotes a gross grape-like growth pattern.

The conventional designation is associated with embryonal rhabdomyosarcoma.

A polypoid lesion alone is not proof of rhabdomyosarcoma.

Microscopic lineage confirmation is still required.

Slide 41 · Embryonal rhabdomyosarcoma: Morphology

Primitive cells

Round and spindle-shaped malignant cells in a myxoid background.

Differentiating cells

Some tumor cells show rhabdomyoblastic cytoplasm or cross-striations.

Growth pattern

Botryoid examples arise beneath epithelial surfaces of hollow viscera.

Slide 42 · The cambium layer: An architectural clue

Botryoid embryonal rhabdomyosarcoma may show dense subepithelial cellularity.

This concentrated band is termed the cambium layer.

Deeper tumor regions may contain a looser myxoid stroma.

The finding helps explain why a superficial polyp can mask malignant tissue.

Slide 43 · From primitive mesenchyme to myogenic phenotype

Conceptual differentiation continuum, not a documented clonal progression sequence.

Undifferentiated cells

Primitive round / spindle morphology.

Partial differentiation

Eosinophilic rhabdomyoblasts may appear.

Lineage demonstration

Myogenin immunoreactivity supports skeletal-muscle differentiation.

Slide 44 · Rhabdomyoblast morphology

Cells may vary from primitive round forms to more differentiated eosinophilic forms.

Some rhabdomyoblasts display cross-striations.

Cross-striations are not required in every diagnostic sample.

Myogenic immunohistochemistry is important when morphologic differentiation is limited.

Slide 45 · Myogenin: A meaningful lineage marker

Myogenin is a skeletal-muscle-associated differentiation protein.

It is useful when confirming rhabdomyoblastic differentiation.

Nuclear myogenin staining supports skeletal-muscle lineage in the right context.

Marker interpretation follows morphology; It is not a substitute for tumor classification.

Slide 46 · Rhabdomyosarcoma is a heterogeneous family

Subtype

Robbins morphologic / molecular description

Embryonal

Primitive cells in myxoid stroma; RAS pathway changes are frequent.

Alveolar

Fibrous septa, dyscohesive cells; PAX3/7::FOXO1 fusions often present.

Spindle cell / sclerosing

Fusiform morphology; subset with MYOD1 alterations.

Pleomorphic

Large bizarre cells; heterogeneous genetics, generally adult.

Slide 47 · Embryonal versus alveolar: A molecular distinction

Embryonal rhabdomyosarcoma frequently has alterations activating RAS signaling.

Alveolar rhabdomyosarcoma frequently carries PAX3::FOXO1 or PAX7::FOXO1 fusions.

These are subtype-level findings, not universal bladder-tumor markers.

A fusion found in one subtype must not be assigned to every embryonal lesion.

Slide 48 · Pediatric pathology: Integrating site and differentiation

Age

Childhood makes embryonal rhabdomyosarcoma particularly relevant.

Site

Genitourinary tract is a recognized pediatric presentation site.

Diagnosis

Architecture plus rhabdomyoblastic differentiation guides classification.

Slide 49 · Case B — a polypoid pediatric lesion

A young child has a large, grape-like bladder mass. Histology demonstrates primitive round and spindle cells in myxoid stroma with a dense subepithelial tumor layer.

Interpretation questions

Which sarcoma subtype is most strongly suggested?

What does the subepithelial cellular band represent?

Which stain may confirm skeletal-muscle differentiation?

Slide 50 · Case B — diagnosis and reasoning

The combination favors botryoid embryonal rhabdomyosarcoma.

Dense subepithelial cellularity is the cambium-layer pattern.

Myogenin can provide evidence of skeletal-muscle differentiation.

The polypoid appearance alone is insufficient without diagnostic tissue.

Slide 51 · Inflammatory myofibroblastic tumor: A key mimic

Robbins explicitly highlights inflammatory myofibroblastic tumor among bladder sarcoma mimics.

A myofibroblastic spindle-cell proliferation may occur with a conspicuous inflammatory infiltrate.

Inflammatory cells do not by themselves prove a reactive or benign process.

Careful morphologic and phenotypic classification prevents overcalling true sarcoma.

Slide 52 · Inflammatory myofibroblastic tumor: Useful clues

Component

Pathologic finding

Spindle cells

Fibroblastic / myofibroblastic proliferation

Background

Lymphocytes and plasma cells may be conspicuous

Stroma

Variable fibrosis and myxoid change

Molecular support

ALK rearrangement is present in a subset of IMTs

Slide 53 · ALK is supportive, not a universal requirement

A subset of inflammatory myofibroblastic tumors harbors activating ALK rearrangements.

ALK immunohistochemistry or molecular evidence may support an IMT diagnosis.

An ALK-negative result cannot, on its own, exclude every IMT.

Lineage and morphology remain necessary in the differential diagnosis.

Slide 54 · Sarcomatoid carcinoma: Avoid a lineage error

Some bladder carcinomas assume a sarcomatoid growth pattern.

A sarcoma-like spindle-cell morphology does not prove primary mesenchymal malignancy.

The possibility of an epithelial neoplasm must be considered before calling a primary sarcoma.

A spindle-cell lesion may require expanded evaluation for epithelial differentiation.

Slide 55 · True sarcoma versus sarcomatoid carcinoma

Decision point

True mesenchymal sarcoma

Sarcomatoid carcinoma

Conceptual origin

Mesenchymal neoplasm

Carcinoma with sarcoma-like phenotype

Routine morphology

May be spindle-cell or pleomorphic

Can mimic a spindle-cell sarcoma

Primary challenge

Assign differentiation and subtype

Seek evidence of epithelial lineage

Interpretive rule

Do not classify by shape alone

Do not classify by shape alone

Slide 56 · Spindle-cell bladder mass: Conceptual work-up

Verify specimen

Review location, depth, architecture and tissue adequacy.

Assess pattern

Bland muscle / malignant fascicles / myxoid inflammation / primitive cells.

Test lineage

Use targeted ancillary markers when morphology remains ambiguous.

Classify

Integrate all findings before giving an entity-level diagnosis.

Slide 57 · Three different biological questions

Question

What primarily answers it?

What lineage is present?

Morphology plus lineage immunostaining, when indicated.

Is the lesion benign or malignant?

Architectural and cytologic behavior across adequate tissue.

What specific entity is it?

Lineage, age, site, morphology and subtype-defining evidence.

How far does it extend?

Depth, local interface and available sampling.

Slide 58 · Adequate specimen assessment is critical

Small biopsies may fail to represent the full perimeter of a mass.

Mitotic hot spots, necrosis, and focal differentiation may be unevenly distributed.

Apparent urothelial coverage is not evidence of urothelial tumor origin.

Statements about complete removal or extension require an appropriately sampled specimen.

Slide 59 · Bladder mesenchymal tumor: Integrated comparison

Entity

Most useful clue

Key pitfall

Leiomyoma

Bland, circumscribed smooth-muscle fascicles

Do not diagnose solely by smooth-muscle marker positivity

Leiomyosarcoma

Atypical smooth-muscle cells + malignant features

Do not infer subtype from gross color

Embryonal RMS

Primitive myogenic cells; possible botryoid growth

Do not equate any polyp with RMS

IMT

Myofibroblastic cells + inflammation; ALK in some

Do not label every spindle-cell lesion sarcoma

Sarcomatoid carcinoma

Carcinoma with sarcoma-like growth

Do not overlook epithelial lineage

Slide 60 · What a pathology report should resolve

Teaching-oriented report checklist, not a formal prescribed synoptic template or staging standard.

Most defensible entity and lineage based on available material.

Presence of relevant malignant histologic features, where assessable.

Anatomic extent and margin status, only when the specimen supports assessment.

Any material limitations or unresolved differential diagnoses.

Slide 61 · Case C — a spindle-cell bladder lesion

A bladder mass shows spindle-shaped cells admixed with lymphocytes and plasma cells. No convincing myogenic rhabdomyoblasts are identified; Ancillary testing is being considered.

Interpretation questions

Which important sarcoma mimic must be considered?

Why would inflammation alone be insufficient for classification?

What could ALK testing contribute, and what could it not establish?

Slide 62 · Case C — managing diagnostic uncertainty

Inflammatory myofibroblastic tumor is a relevant differential diagnosis.

Inflammatory infiltrates can accompany neoplastic growth; Pattern recognition remains essential.

Positive ALK findings may support IMT in the appropriate context.

Negative ALK alone does not eliminate other spindle-cell differential diagnoses.

Slide 63 · Case D — a malignant adult spindle-cell mass

An adult bladder tumor is large, soft, fleshy and gray-white. The tissue contains atypical eosinophilic spindle cells in fascicles, with brisk mitoses and necrosis.

Interpretation questions

Which primary sarcoma is favored by the differentiation?

Which features provide evidence of malignancy?

Which bladder tumor mimic still requires exclusion?

Slide 64 · Case D — synthesis of the differential

Leiomyosarcoma is favored by malignant smooth-muscle morphology.

Atypia, mitoses and necrosis indicate an aggressive morphologic pattern.

Smooth-muscle lineage stains may support differentiation, but not behavior alone.

Sarcomatoid carcinoma remains a critical competing diagnosis.

Slide 65 · One diagnostic principle across all four cases

Gross / clinical

Establish location, age and mass configuration.

Histology

Evaluate architecture, cytology and growth interface.

Ancillary studies

Resolve differentiation and relevant differentials.

Integrated answer

Report a defensible entity with appropriate limitations.

Slide 66 · Ten points worth retaining

Bladder mesenchymal tumors are rare; Leiomyoma is the leading benign example.

True sarcoma is uncommon; Adult leiomyosarcoma and childhood embryonal RMS are key types.

Botryoid morphology is a polypoid pattern that needs myogenic confirmation.

Spindle-cell mimics, especially sarcomatoid carcinoma and IMT, demand consideration.

Slide 67 · Evidence boundaries for this lecture

Established bladder facts

The dominant benign and malignant entities and their characteristic gross patterns.

Transferable principles

Comparable smooth-muscle, skeletal-muscle and inflammatory myofibroblastic morphology.

Important limits

No bladder-specific prevalence tables, molecular frequencies, staging cutoffs or treatment protocols are asserted.

Slide 68 · References and further reading

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 21, p. 875.

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 26, pp. 1102–1103.

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 22, p. 904; Chapter 15, IMT section.

Source mapping, cross-organ limitations and visual provenance are recorded in speaker notes.